[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100120045":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":7,"locations":22,"responsibleParty":28,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":38,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","AZD2066","1 dose oral solution",[14,18],{"name":15,"affiliation":16,"role":17},"Emeline Ramos, MD","AstraZeneca R&D, CPU Alderley Park, UK","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":20,"role":21},"Lars Ståhle, MD","AstraZeneca R&D, Södertälje, Sweden","STUDY_CHAIR",[23],{"facility":24,"status":7,"city":25,"state":7,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":7,"geoPoint":7,"contacts":7},"Research Site","Cheshire","United Kingdom","UK",{"type":7,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":29,"oldOrganization":30},"Rolf Karlsten, MD, PhD, Medical Science Director, Emerging Analgesia, Neuroscience","AstraZeneca R&D Södertälje, Sweden","100120045","phase-1-investigation-of-rate--extent-of-excretion-of-radioactivity-in-urine-faeces-after-oral-administration-of-14cazd2066-100120045",false,"NCT00829088","Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066","An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects","Inclusion Criteria:\n\n* Provision of signed informed consent\n* Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG.\n\nExclusion Criteria:\n\n* History of somatic disease\u002Fcondition, which may interfere with the objectives of the study.\n* History of previous or ongoing psychiatric disease\u002Fcondition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder.\n* Healthy volunteers who have been exposed to radiation levels above background (eg, through X-ray examinations).",true,"MALE","35 Years","50 Years",{"count":43,"type":44},6,"ACTUAL","INTERVENTIONAL",[47],"PHASE1","The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.",[50],"Pain",[52,11,50,53],"Mass balance","Pain conditions","COMPLETED","2009-02-24",{"date":57,"type":58},"2009-02-25","ESTIMATED",{"date":60,"type":7},"2009-01",{"date":62,"type":44},"2009-02",{"name":5,"class":6},1]